Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract 5144: Epigenetic reprogramming by tumor-derived EZH2 gain of function mutants leads to aggressive 3D-cell morphologies in both epithelial and melanoma cells

Robert A. Rollins, Anthony M. Barsotti, Michael Ryskin, Wenyan Zhong, Wei-Guo Zhang, Andreas Giannakou, Christine Loreth, Veronica Diesl, Maximillian T. Follettie, Jonathon Golas, Michelle Lee, Timothy Nichols, Conglin Fan, Gary Li, Stephen Dann, Paul A. Rejto, Kim T. Arndt, Dominique Verhelle

Cancer Res (2014) 74 (19_Supplement): 5144.

https://doi.org/10.1158/1538-7445.AM2014-5144

Published: 01 October 2014

View article titled, Abstract 5144: Epigenetic reprogramming by tumor-derived EZH2 gain of function mutants leads to aggressive 3D-cell morphologies in both epithelial and melanoma cells

Journal Articles

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Cancer Res (2010) 70 (2): 621–631.

https://doi.org/10.1158/0008-5472.CAN-09-2340

Published: 13 January 2010

View article titled, Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Includes: Supplementary data

Journal Articles

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Ker Yu, Lourdes Toral-Barza, Celine Shi, Wei-Guo Zhang, Judy Lucas, Boris Shor, Jamie Kim, Jeroen Verheijen, Kevin Curran, David J. Malwitz, Derek C. Cole, John Ellingboe, Semiramis Ayral-Kaloustian, Tarek S. Mansour, James J. Gibbons, Robert T. Abraham, Pawel Nowak, Arie Zask

Cancer Res (2009) 69 (15): 6232–6240.

https://doi.org/10.1158/0008-5472.CAN-09-0299

Published: 29 July 2009

View article titled, Biochemical, Cellular, and <em>In vivo</em> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Includes: Supplementary data

Journal Articles

Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Cancer Res (2009) 69 (9_Supplement): 3713.

Published: 01 May 2009

View article titled, Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Journal Articles

Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

Arie Zask, Jeroen Verheijen, Joshua Kaplan, Kevin Curran, David Richard, Natasja Brooijmans, Judy Lucas, Lourdes Toral-Barza, Wei-Guo Zhang, Irwin Hollander, James Gibbons, Robert Abraham, Semiramis Ayral-Kaloustian, Tarek Mansour, Ker Yu

Cancer Res (2009) 69 (9_Supplement): 2014.

Published: 01 May 2009

View article titled, Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

Journal Articles

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Boris Shor, Wei-Guo Zhang, Lourdes Toral-Barza, Jessica Lucas, Robert T. Abraham, James J. Gibbons, Ker Yu

Cancer Res (2008) 68 (8): 2934–2943.

https://doi.org/10.1158/0008-5472.CAN-07-6487

Published: 15 April 2008

View article titled, A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Includes: Supplementary data

NARROW

Abstract 5144: Epigenetic reprogramming by tumor-derived EZH2 gain of function mutants leads to aggressive 3D-cell morphologies in both epithelial and melanoma cells

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Email alerts

AACR Journals

Abstract 5144: Epigenetic reprogramming by tumor-derived EZH2 gain of function mutants leads to aggressive 3D-cell morphologies in both epithelial and melanoma cells

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only